FMS vs NVA vs DVA vs USAS

For growth investors, DaVita Inc.

(DVA) is the stronger pick with 6. 5% revenue growth year-over-year, versus 1. 5% for Fresenius Medical Care AG & Co. KGaA (FMS). Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11. 0x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Americas Gold and Silver Corporation (USAS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Fresenius Medical Care AG & Co.

KGaA (FMS) is the cheapest at 11. 0x versus DaVita Inc. at 20. 6x. On forward P/E, Fresenius Medical Care AG & Co. KGaA is actually cheaper at 10. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: DaVita Inc. wins at 1. 67x versus Fresenius Medical Care AG & Co. KGaA's 2. 06x — a reasonable growth-adjusted valuation.

Over the past 5 years, DaVita Inc.

(DVA) delivered a total return of +54. 8%, compared to -35. 9% for Fresenius Medical Care AG & Co. KGaA (FMS). Over 10 years, the gap is even starker: DVA returned +158. 1% versus FMS's -35. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DaVita Inc.

(DVA) is the lower-risk stock at 0. 05β versus Americas Gold and Silver Corporation's 2. 31β — meaning USAS is approximately 4764% more volatile than DVA relative to the S&P 500. On balance sheet safety, Americas Gold and Silver Corporation (USAS) carries a lower debt/equity ratio of 45% versus 13% for DaVita Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DaVita Inc.

(DVA) is pulling ahead at 6. 5% versus 1. 5% for Fresenius Medical Care AG & Co. KGaA (FMS). On earnings-per-share growth, the picture is similar: Fresenius Medical Care AG & Co. KGaA grew EPS 82. 6% year-over-year, compared to -11. 4% for DaVita Inc.. Over a 3-year CAGR, USAS leads at 30. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DaVita Inc.

(DVA) is the more profitable company, earning 5. 5% net margin versus -44. 9% for Americas Gold and Silver Corporation — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DVA leads at 14. 7% versus -26. 2% for USAS. At the gross margin level — before operating expenses — DVA leads at 27. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, DaVita Inc. (DVA) is the more undervalued stock at a PEG of 1. 67x versus Fresenius Medical Care AG & Co. KGaA's 2. 06x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Fresenius Medical Care AG & Co. KGaA (FMS) trades at 10. 5x forward P/E versus 26. 3x for Americas Gold and Silver Corporation — 15. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USAS: 52. 8% to $9. 75.

In this comparison, FMS (3.

8% yield) pays a dividend. NVA, DVA, USAS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, DaVita Inc.

(DVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), +158. 1% 10Y return). Americas Gold and Silver Corporation (USAS) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DVA: +158. 1%, USAS: -5. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (FMS (Healthcare) and NVA (Basic Materials) and DVA (Healthcare) and USAS (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: FMS is a mid-cap deep-value stock; NVA is a small-cap quality compounder stock; DVA is a mid-cap quality compounder stock; USAS is a small-cap quality compounder stock. FMS pays a dividend while NVA, DVA, USAS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.